Bio-rad Laboratories Stock News

Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.

Bio-Rad Laboratories continues to report impressive earnings and has been on a winning streak with nearly two years of strong beats on EPS and revenue. The company's expansive product portfolio has fa

Nelson Van Denburg & Campbell Wealth Management Group LLC lessened its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 16.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,208 shares of the medical research companys stock after selling 231 shares during the []

Here is how Bio-Rad Laboratories (BIO) and Fullgent Genetics (FLGT) have performed compared to their sector so far this year.

Key Prominent Players Covered in the Cell Freezing Media Market are Thermo Fisher Scientific, Bio-Rad Laboratories, Abcam Plc, Merck KGaA, BioLifeSolutions Inc., HiMedia Laboratories, AMSBIO, BIOGENUIX MEDSYSTEM PVT.LTD. Key Prominent Players Covered in the Cell Freezing Media Market are Thermo Fisher Scientific, Bio-Rad Laboratories, Abcam Plc, Merck KGaA, BioLifeSolutions Inc., HiMedia Laboratories, AMSBIO, BIOGENUIX MEDSYSTEM PVT.LTD.

This report studies the Global Autoimmunity Reagents Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)s stock price reached a new 52-week high during trading on Tuesday . The company traded as high as $722.91 and last traded at $722.91, with a volume of 6 shares. The stock had previously closed at $722.91. The business has a fifty day simple moving average of $744.09 and a 200 []

Bio-Rad Laboratories (NYSE:BIO.B) and IsoPlexis (NASDAQ:ISO) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Earnings and Valuation This table compares Bio-Rad Laboratories and IsoPlexis top-line revenue, earnings per share and valuation. [] The post Critical Contrast: Bio-Rad Laboratories (NYSE:BIO.B) and IsoPlexis (NASDAQ:ISO) appeared first on ETF Daily News .

This Infertility Testing And Treatment market report analyzed the market conditions of key region of the world including product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. The report introduced the new project SWOT analysis,

Related Stocks: CTRA , NEM , DLR , AEP , CTXS , DLTR , BAX , NOW , OGN , BIO , CBOE ,

Bio-Rad Laboratories, Inc. (NYSE:BIO.B) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $750.16 and last traded at $750.16, with a volume of 8 shares traded. The stock had previously closed at $750.16. The firm has a market cap of $22.44 billion, a price-to-earnings ratio of 3.40 […]

Biome Australia Ltd (ASX:BIO) insider Blair Norfolk acquired 174,600 shares of the companys stock in a transaction dated Friday, December 10th. The stock was bought at an average cost of A$0.10 ($0.07) per share, for a total transaction of A$17,634.60 ($12,596.14). About Biome Australia Bio-Rad Laboratories, Inc is a global leader in developing, manufacturing, and []

Related Stocks: RGEN , DASH , NTLA , ABNB , MNDY , BIO , CRL , S , S , 0A8V , FRSH , FRSH , PINS , WIX , CSGP , NARI , ZEN , GH , 7974 , UBER , RNG , QTWO , 03690 , EQIX ,